An extensive study of propelling opportunities in, “mRNA Vaccines Market Size, Share & Trends Analysis Report by Vaccine Type (Prophylactic Vaccines (Infectious Disease Vaccines, Cancer Prevention Vaccines, Others), Therapeutic Vaccines (Cancer Immunotherapy, Autoimmune Disease Treatment, Rare Disease Treatment, Others), Technology Platform, Disease Indication, Delivery Method, Route of Administration, Dosage Form, Development Stage, End-users and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A comprehensive report of growing market landscapes in the mRNA vaccines sector uncovering key growth drivers including niche market leadership, technology-enabled distribution, and increasing consumer needs supporting mRNA vaccines market potential to scale globally.
Global mRNA Vaccines Market Forecast 2035:
According to the report, the mRNA vaccines market is anticipated to grow from USD 10.3 Billion in 2025 to USD 39.5 Billion in 2035 at a CAGR of 14.4% during the forecast. The presence of explosive growth currently seen in the mRNA vaccines market is being driven by a heightened awareness of preventing infectious disease, increasing rates of infectious and chronic disease, and increasing acceptance of next-generation vaccine technology throughout North America and Europe. Strategic partnerships between biotechnology companies, pharmaceutical companies, and publicly-funded health organizations are increasing research capacity and increasing development timelines. Also, investments in new delivery platforms, especially lipid nanoparticles, are increasing efficacy and stability of mRNA vaccines.
Despite the promise of mRNA vaccines, high production costs, cold-chain logistics, and policy regulatory environments may represent barriers to growth. In addition, the continued adoption of AI-informed drug discovery and predictive analytics are likely only going to further optimize mRNA vaccine design, shorten clinical timeline, and inform personalized vaccination strategies across both developing and developed economies.
Moreover, new developments in global pandemic preparedness and shifts toward preventative models of healthcare are also helping to drive growth in the mRNA vaccine market. New investment in robust manufacturing and scalable cold-storage solutions is going to further increase accessibility and secure distribution of mRNA vaccines in the global mRNA vaccines market.
“Key Driver, Restraint, and Growth Opportunity Defining the Global mRNA Vaccines Market”
The global mRNA vaccines market experiences growth, driven by the increasing occurrence of infectious diseases and chronic conditions, and emphasis on preventative health and rapid preparedness against future pathogens. Advances in vaccine delivery technology, artificial intelligence-powered research, and digital healthcare environments will continue to drive growth opportunities by expediting development, enabling more individualized vaccination approaches, and enhancing vaccine monitoring to better assess safety and effectiveness issues.
Challenges to mRNA vaccines market expansion include considerable costs associated with the manufacturing and distribution of mRNA vaccines, issues with cold-chain complexity, and regulatory oversight and frameworks that vary internationally. Access equity barriers, particularly in low-resource environments, insurance coverage for newer vaccine technologies, and logistical organization may also limit uptake of the mRNA delivery system.
Such barriers to uptake should be seen as legitimate factors, with potential for expansion with new mRNA vaccine delivery systems, the resurgence of collaborative work between biotech companies and governments, and the increasing willingness to accept mRNA vaccines from the general public. Further investments in scalable infrastructure, advanced vaccine delivery technology and individualized data information systems to improve vaccine monitoring will also support and build a framework for continued expansion in the mRNA vaccines market.
"Impact of Global Tariff Policies on the Global mRNA Vaccines Market Growth and Strategy"
International tariffs impact the mRNA vaccines market by increasing the cost of critical raw materials, reagents, and specialized delivery systems. For instance, tariffs on lipid nanoparticles, nucleotides, or cold-chain equipment imported from countries such as China or India can significantly raise production costs for mRNA vaccine manufacturers. If these costs are passed on to healthcare providers or patients, access to life-saving vaccines could be constrained, particularly in price-sensitive regions.
Further in order to mitigate these supply-side challenges, many companies are diversifying their supply chains, sourcing materials from multiple regions, or investing in domestic production facilities to reduce dependency on offshore suppliers. Additionally, manufacturers are leveraging automation, AI-driven process optimization, and advanced manufacturing technologies to improve efficiency and contain costs. Policymakers must consider the implications of trade and tariff policies on vaccine affordability, accessibility, and global immunization efforts when formulating regulations affecting the mRNA vaccines market.
Expansion of Global mRNA Vaccines Market
“Rising Infectious Diseases, Advanced Vaccine Technologies, and Global Manufacturing Investments Drive mRNA Vaccine Market Expansion”
- The global mRNA vaccines market is growing rapidly due to the increase in infectious diseases, advancement in vaccine technology, and additional funding in global manufacturing capacity. The rise in infectious diseases, including seasonal influenza, new viral pathogens, and some chronic viral infections, has created a demand for fast-acting, effective vaccines, while consideration for preventative healthcare and pandemic preparedness is further driving adoption.
- Meanwhile, advances in mRNA vaccines, such as lipid nanoparticle (LNP) delivery systems, self-amplifying mRNA, and thermostable formulations are leading to greater efficacy, stability, and distribution capabilities. Research and predictive analytics driven by artificial intelligence will also accelerate antigen selection, dosing regimens, and trial design of clinical research for more effective and individualized immunizations.
- In light of investments in manufacturing capacity in several domestic and regional facilities, production capabilities are expanding, while limiting dependence on restrictive supply chains, and greater access to global markets. Collaboration consortiums (e.g., between biotechnology, pharmaceutical, and governmental organizations) will also improve capacity, expertise, and rapid development of vaccines during an outbreak, providing strong opportunities for continued event-driven growth in the mRNA vaccines market.
Regional Analysis of Global mRNA Vaccines Market
- The global mRNA vaccines market is growing steadily, driven by advancements in biotechnology and a growing focus on personalized medicine. North America - particularly the U.S. and Canada - has established healthcare systems, high insurance coverage rates, and a growing shift towards home-based care (all contributing to growth in the mRNA Vaccines market). Europe, primarily Germany, the UK, and France, has the largest market based on their established public healthcare systems and long history in providing home healthcare services within their healthcare systems.
- The Asia-Pacific mRNA vaccines market is expected to grow significantly, with countries such as China, India, and Japan seeing increases in demand for mRNA Vaccines, as their populations age, healthcare investment grows, and public awareness increases towards the benefits of immunization.
- Latin America and the Middle East & Africa also present growth potential, driven by vaccination programs growing in capacity and capability (including reaching patients at home), and policy decisions to improve healthcare infrastructure in general that will allow for improved adoption of mRNA Vaccines to be delivered in hospitals and in-home care.
Key players in the global mRNA vaccines market include prominent companies such as Acuitas Therapeutics, Arcturus Therapeutics Holdings Inc., Argos Therapeutics Inc., AstraZeneca plc, BioNTech SE, CureVac N.V., eTheRNA Immunotherapies, Ethris GmbH, Gritstone bio Inc., GSK plc (GlaxoSmithKline), Merck & Co. Inc., Moderna Inc., Novartis AG, Pfizer Inc., Providence Therapeutics Holdings Inc., Sanofi S.A., Stemirna Therapeutics, Translate Bio (Sanofi), Walvax Biotechnology Co. Ltd., along with several other key players contributing to market growth through innovation, strategic partnerships, and global expansion.
The global mRNA vaccines market has been segmented as follows:
Global mRNA Vaccines Market Analysis, by Vaccine Type
- Prophylactic Vaccines
- Infectious Disease Vaccines
- Cancer Prevention Vaccines
- Others
- Therapeutic Vaccines
- Cancer Immunotherapy
- Autoimmune Disease Treatment
- Rare Disease Treatment
- Others
Global mRNA Vaccines Market Analysis, by Technology Platform
- Conventional mRNA
- Self-Amplifying mRNA (SAM)
- Trans-Amplifying mRNA (TAM)
- Circular mRNA
- Bi-cistronic mRNA
Global mRNA Vaccines Market Analysis, by Disease Indication
- Infectious Diseases
- COVID-19
- Influenza
- Zika Virus
- Cytomegalovirus (CMV)
- Respiratory Syncytial Virus (RSV)
- HIV/AIDS
- Rabies
- Ebola
- Others
- Oncology
- Melanoma
- Lung Cancer
- Breast Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Others
- Rare Diseases
- Cardiovascular Diseases
- Autoimmune Disorders
Global mRNA Vaccines Market Analysis, by Delivery Method
- Lipid Nanoparticles (LNP)
- Polymer-based Nanoparticles
- Peptide-based Delivery
- Protamine-based Delivery
- Naked mRNA Delivery
- Cationic Nanoemulsion
Global mRNA Vaccines Market Analysis, by Route of Administration
- Intramuscular Injection
- Intradermal Injection
- Subcutaneous Injection
- Intravenous Injection
- Intranasal Administration
- Intratumoral Injection
Global mRNA Vaccines Market Analysis, by Dosage Form
- Single-dose Vials
- Multi-dose Vials
- Pre-filled Syringes
- Lyophilized Powder
- Ready-to-use Liquid Formulation
Global mRNA Vaccines Market Analysis, by Development Stage
- Preclinical Stage
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Approved/Commercialized
Global mRNA Vaccines Market Analysis, by End-users
- Research & Development
- Drug Discovery
- Clinical Trial Research
- Platform Technology Development
- Biomarker Studies
- Preclinical Testing
- Others
- Healthcare & Clinical Settings
- Disease Prevention Programs
- Treatment & Therapeutics
- Emergency Pandemic Response
- Routine Immunization
- Cancer Therapy
- Personalized Medicine
- Others
- Public Health Programs
- Mass Vaccination Campaigns
- Epidemic/Pandemic Control
- Immunization Outreach
- Disease Surveillance
- Preventive Healthcare
- Personalized Medicine
- Others
- Pharmaceutical & Biotechnology Companies
- Commercial Manufacturing
- Product Development
- Quality Control & Testing
- Technology Licensing
- Contract Manufacturing
- Others
- Academic & Government Institutions
- Basic Research
- Clinical Studies
- Regulatory Assessment
- Technology Transfer
- Educational Training
- Others
- Other End-users
Global mRNA Vaccines Market Analysis, by Region
- North America
- Europe
- Asia Pacific
- Middle East
- Africa
- South America
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact US
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global mRNA Vaccines Market Outlook
- 2.1.1. Global mRNA Vaccines Market Size (Value - USD Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global mRNA Vaccines Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
- 3.4.1. Import & Export Analysis, 2025
- 3.4.2. Top Importing Countries
- 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
- 3.5.1. Manufacturer
- 3.5.2. Supply Chain
- 3.5.3. End Consumer
- 3.6. Raw Material Analysis
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Rising prevalence of infectious and chronic diseases.
- 4.1.1.2. Advancements in lipid nanoparticle (LNP) delivery technologies.
- 4.1.1.3. Increasing government and private investments in vaccine R&D.
- 4.1.2. Restraints
- 4.1.2.1. High production and storage costs due to temperature-sensitive formulations.
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.4.1. Raw Material Suppliers
- 4.4.2. mRNA Vaccines Manufacturers
- 4.4.3. Distributors and Logistics
- 4.4.4. End Users/ Customers
- 4.5. Cost Structure Analysis
- 4.5.1. Parameter’s Share for Cost Associated
- 4.5.2. COGP vs COGS
- 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
- 4.6.1. Regional Pricing Analysis
- 4.6.2. Segmental Pricing Trends
- 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Global mRNA Vaccines Market Demand
- 4.9.1. Historical Market Size – (Value - USD Bn), 2021-2024
- 4.9.2. Current and Future Market Size – (Value - USD Bn), 2025–2035
- 4.9.2.1. Y-o-Y Growth Trends
- 4.9.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global mRNA Vaccines Market Analysis, by Vaccine Type
- 6.1. Key Segment Analysis
- 6.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Vaccine Type, 2021-2035
- 6.2.1. Prophylactic Vaccines
- 6.2.1.1. Infectious Disease Vaccines
- 6.2.1.2. Cancer Prevention Vaccines
- 6.2.1.3. Others
- 6.2.2. Therapeutic Vaccines
- 6.2.2.1. Cancer Immunotherapy
- 6.2.2.2. Autoimmune Disease Treatment
- 6.2.2.3. Rare Disease Treatment
- 6.2.2.4. Others
- 6.2.1. Prophylactic Vaccines
- 7. Global mRNA Vaccines Market Analysis, by Technology Platform
- 7.1. Key Segment Analysis
- 7.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Technology Platform, 2021-2035
- 7.2.1. Conventional mRNA
- 7.2.2. Self-Amplifying mRNA (SAM)
- 7.2.3. Trans-Amplifying mRNA (TAM)
- 7.2.4. Circular mRNA
- 7.2.5. Bi-cistronic mRNA
- 8. Global mRNA Vaccines Market Analysis, by Disease Indication
- 8.1. Key Segment Analysis
- 8.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Disease Indication, 2021-2035
- 8.2.1. Infectious Diseases
- 8.2.1.1. COVID-19
- 8.2.1.2. Influenza
- 8.2.1.3. Zika Virus
- 8.2.1.4. Cytomegalovirus (CMV)
- 8.2.1.5. Respiratory Syncytial Virus (RSV)
- 8.2.1.6. HIV/AIDS
- 8.2.1.7. Rabies
- 8.2.1.8. Ebola
- 8.2.1.9. Others
- 8.2.2. Oncology
- 8.2.2.1. Melanoma
- 8.2.2.2. Lung Cancer
- 8.2.2.3. Breast Cancer
- 8.2.2.4. Pancreatic Cancer
- 8.2.2.5. Colorectal Cancer
- 8.2.2.6. Others
- 8.2.3. Rare Diseases
- 8.2.4. Cardiovascular Diseases
- 8.2.5. Autoimmune Disorders
- 8.2.1. Infectious Diseases
- 9. Global mRNA Vaccines Market Analysis, by Delivery Method
- 9.1. Key Segment Analysis
- 9.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Delivery Method, 2021-2035
- 9.2.1. Lipid Nanoparticles (LNP)
- 9.2.2. Polymer-based Nanoparticles
- 9.2.3. Peptide-based Delivery
- 9.2.4. Protamine-based Delivery
- 9.2.5. Naked mRNA Delivery
- 9.2.6. Cationic Nanoemulsion
- 10. Global mRNA Vaccines Market Analysis, by Route of Administration
- 10.1. Key Segment Analysis
- 10.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
- 10.2.1. Intramuscular Injection
- 10.2.2. Intradermal Injection
- 10.2.3. Subcutaneous Injection
- 10.2.4. Intravenous Injection
- 10.2.5. Intranasal Administration
- 10.2.6. Intratumoral Injection
- 11. Global mRNA Vaccines Market Analysis, by Dosage Form
- 11.1. Key Segment Analysis
- 11.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Dosage Form, 2021-2035
- 11.2.1. Single-dose Vials
- 11.2.2. Multi-dose Vials
- 11.2.3. Pre-filled Syringes
- 11.2.4. Lyophilized Powder
- 11.2.5. Ready-to-use Liquid Formulation
- 12. Global mRNA Vaccines Market Analysis, by Development Stage
- 12.1. Key Segment Analysis
- 12.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Development Stage, 2021-2035
- 12.2.1. Preclinical Stage
- 12.2.2. Phase I Clinical Trials
- 12.2.3. Phase II Clinical Trials
- 12.2.4. Phase III Clinical Trials
- 12.2.5. Approved/Commercialized
- 13. Global mRNA Vaccines Market Analysis, by End-users
- 13.1. Key Segment Analysis
- 13.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by End-users, 2021-2035
- 13.2.1. Research & Development
- 13.2.1.1. Drug Discovery
- 13.2.1.2. Clinical Trial Research
- 13.2.1.3. Platform Technology Development
- 13.2.1.4. Biomarker Studies
- 13.2.1.5. Preclinical Testing
- 13.2.1.6. Others
- 13.2.2. Healthcare & Clinical Settings
- 13.2.2.1. Disease Prevention Programs
- 13.2.2.2. Treatment & Therapeutics
- 13.2.2.3. Emergency Pandemic Response
- 13.2.2.4. Routine Immunization
- 13.2.2.5. Cancer Therapy
- 13.2.2.6. Personalized Medicine
- 13.2.2.7. Others
- 13.2.3. Public Health Programs
- 13.2.3.1. Mass Vaccination Campaigns
- 13.2.3.2. Epidemic/Pandemic Control
- 13.2.3.3. Immunization Outreach
- 13.2.3.4. Disease Surveillance
- 13.2.3.5. Preventive Healthcare
- 13.2.3.6. Personalized Medicine
- 13.2.3.7. Others
- 13.2.4. Pharmaceutical & Biotechnology Companies
- 13.2.4.1. Commercial Manufacturing
- 13.2.4.2. Product Development
- 13.2.4.3. Quality Control & Testing
- 13.2.4.4. Technology Licensing
- 13.2.4.5. Contract Manufacturing
- 13.2.4.6. Others
- 13.2.5. Academic & Government Institutions
- 13.2.5.1. Basic Research
- 13.2.5.2. Clinical Studies
- 13.2.5.3. Regulatory Assessment
- 13.2.5.4. Technology Transfer
- 13.2.5.5. Educational Training
- 13.2.5.6. Others
- 13.2.6. Other End-users
- 13.2.1. Research & Development
- 14. Global mRNA Vaccines Market Analysis and Forecasts, by Region
- 14.1. Key Findings
- 14.2. Global mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, by Region, 2021-2035
- 14.2.1. North America
- 14.2.2. Europe
- 14.2.3. Asia Pacific
- 14.2.4. Middle East
- 14.2.5. Africa
- 14.2.6. South America
- 15. North America mRNA Vaccines Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. North America mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Vaccine Type
- 15.3.2. Technology Platform
- 15.3.3. Disease Indication
- 15.3.4. Delivery Method
- 15.3.5. Route of Administration
- 15.3.6. Dosage Form
- 15.3.7. Development Stage
- 15.3.8. End-users
- 15.3.9. Country
- 15.3.9.1. USA
- 15.3.9.2. Canada
- 15.3.9.3. Mexico
- 15.4. USA mRNA Vaccines Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Vaccine Type
- 15.4.3. Technology Platform
- 15.4.4. Disease Indication
- 15.4.5. Delivery Method
- 15.4.6. Route of Administration
- 15.4.7. Dosage Form
- 15.4.8. Development Stage
- 15.4.9. End-users
- 15.5. Canada mRNA Vaccines Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Vaccine Type
- 15.5.3. Technology Platform
- 15.5.4. Disease Indication
- 15.5.5. Delivery Method
- 15.5.6. Route of Administration
- 15.5.7. Dosage Form
- 15.5.8. Development Stage
- 15.5.9. End-users
- 15.6. Mexico mRNA Vaccines Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Vaccine Type
- 15.6.3. Technology Platform
- 15.6.4. Disease Indication
- 15.6.5. Delivery Method
- 15.6.6. Route of Administration
- 15.6.7. Dosage Form
- 15.6.8. Development Stage
- 15.6.9. End-users
- 16. Europe mRNA Vaccines Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Europe mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Vaccine Type
- 16.3.2. Technology Platform
- 16.3.3. Disease Indication
- 16.3.4. Delivery Method
- 16.3.5. Route of Administration
- 16.3.6. Dosage Form
- 16.3.7. Development Stage
- 16.3.8. End-users
- 16.3.9. Country
- 16.3.9.1. Germany
- 16.3.9.2. United Kingdom
- 16.3.9.3. France
- 16.3.9.4. Italy
- 16.3.9.5. Spain
- 16.3.9.6. Netherlands
- 16.3.9.7. Nordic Countries
- 16.3.9.8. Poland
- 16.3.9.9. Russia & CIS
- 16.3.9.10. Rest of Europe
- 16.4. Germany mRNA Vaccines Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Vaccine Type
- 16.4.3. Technology Platform
- 16.4.4. Disease Indication
- 16.4.5. Delivery Method
- 16.4.6. Route of Administration
- 16.4.7. Dosage Form
- 16.4.8. Development Stage
- 16.4.9. End-users
- 16.5. United Kingdom mRNA Vaccines Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Vaccine Type
- 16.5.3. Technology Platform
- 16.5.4. Disease Indication
- 16.5.5. Delivery Method
- 16.5.6. Route of Administration
- 16.5.7. Dosage Form
- 16.5.8. Development Stage
- 16.5.9. End-users
- 16.6. France mRNA Vaccines Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Vaccine Type
- 16.6.3. Technology Platform
- 16.6.4. Disease Indication
- 16.6.5. Delivery Method
- 16.6.6. Route of Administration
- 16.6.7. Dosage Form
- 16.6.8. Development Stage
- 16.6.9. End-users
- 16.7. Italy mRNA Vaccines Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Vaccine Type
- 16.7.3. Technology Platform
- 16.7.4. Disease Indication
- 16.7.5. Delivery Method
- 16.7.6. Route of Administration
- 16.7.7. Dosage Form
- 16.7.8. Development Stage
- 16.7.9. End-users
- 16.8. Spain mRNA Vaccines Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Vaccine Type
- 16.8.3. Technology Platform
- 16.8.4. Disease Indication
- 16.8.5. Delivery Method
- 16.8.6. Route of Administration
- 16.8.7. Dosage Form
- 16.8.8. Development Stage
- 16.8.9. End-users
- 16.9. Netherlands mRNA Vaccines Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Vaccine Type
- 16.9.3. Technology Platform
- 16.9.4. Disease Indication
- 16.9.5. Delivery Method
- 16.9.6. Route of Administration
- 16.9.7. Dosage Form
- 16.9.8. Development Stage
- 16.9.9. End-users
- 16.10. Nordic Countries mRNA Vaccines Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Vaccine Type
- 16.10.3. Technology Platform
- 16.10.4. Disease Indication
- 16.10.5. Delivery Method
- 16.10.6. Route of Administration
- 16.10.7. Dosage Form
- 16.10.8. Development Stage
- 16.10.9. End-users
- 16.11. Poland mRNA Vaccines Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Vaccine Type
- 16.11.3. Technology Platform
- 16.11.4. Disease Indication
- 16.11.5. Delivery Method
- 16.11.6. Route of Administration
- 16.11.7. Dosage Form
- 16.11.8. Development Stage
- 16.11.9. End-users
- 16.12. Russia & CIS mRNA Vaccines Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Vaccine Type
- 16.12.3. Technology Platform
- 16.12.4. Disease Indication
- 16.12.5. Delivery Method
- 16.12.6. Route of Administration
- 16.12.7. Dosage Form
- 16.12.8. Development Stage
- 16.12.9. End-users
- 16.13. Rest of Europe mRNA Vaccines Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Vaccine Type
- 16.13.3. Technology Platform
- 16.13.4. Disease Indication
- 16.13.5. Delivery Method
- 16.13.6. Route of Administration
- 16.13.7. Dosage Form
- 16.13.8. Development Stage
- 16.13.9. End-users
- 17. Asia Pacific mRNA Vaccines Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. East Asia mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Vaccine Type
- 17.3.2. Technology Platform
- 17.3.3. Disease Indication
- 17.3.4. Delivery Method
- 17.3.5. Route of Administration
- 17.3.6. Dosage Form
- 17.3.7. Development Stage
- 17.3.8. End-users
- 17.3.9. Country
- 17.3.9.1. China
- 17.3.9.2. India
- 17.3.9.3. Japan
- 17.3.9.4. South Korea
- 17.3.9.5. Australia and New Zealand
- 17.3.9.6. Indonesia
- 17.3.9.7. Malaysia
- 17.3.9.8. Thailand
- 17.3.9.9. Vietnam
- 17.3.9.10. Rest of Asia-Pacific
- 17.4. China mRNA Vaccines Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Vaccine Type
- 17.4.3. Technology Platform
- 17.4.4. Disease Indication
- 17.4.5. Delivery Method
- 17.4.6. Route of Administration
- 17.4.7. Dosage Form
- 17.4.8. Development Stage
- 17.4.9. End-users
- 17.5. India mRNA Vaccines Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Vaccine Type
- 17.5.3. Technology Platform
- 17.5.4. Disease Indication
- 17.5.5. Delivery Method
- 17.5.6. Route of Administration
- 17.5.7. Dosage Form
- 17.5.8. Development Stage
- 17.5.9. End-users
- 17.6. Japan mRNA Vaccines Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Vaccine Type
- 17.6.3. Technology Platform
- 17.6.4. Disease Indication
- 17.6.5. Delivery Method
- 17.6.6. Route of Administration
- 17.6.7. Dosage Form
- 17.6.8. Development Stage
- 17.6.9. End-users
- 17.7. South Korea mRNA Vaccines Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Vaccine Type
- 17.7.3. Technology Platform
- 17.7.4. Disease Indication
- 17.7.5. Delivery Method
- 17.7.6. Route of Administration
- 17.7.7. Dosage Form
- 17.7.8. Development Stage
- 17.7.9. End-users
- 17.8. Australia and New Zealand mRNA Vaccines Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Vaccine Type
- 17.8.3. Technology Platform
- 17.8.4. Disease Indication
- 17.8.5. Delivery Method
- 17.8.6. Route of Administration
- 17.8.7. Dosage Form
- 17.8.8. Development Stage
- 17.8.9. End-users
- 17.9. Indonesia mRNA Vaccines Market
- 17.9.1. Country Segmental Analysis
- 17.9.2. Vaccine Type
- 17.9.3. Technology Platform
- 17.9.4. Disease Indication
- 17.9.5. Delivery Method
- 17.9.6. Route of Administration
- 17.9.7. Dosage Form
- 17.9.8. Development Stage
- 17.9.9. End-users
- 17.10. Malaysia mRNA Vaccines Market
- 17.10.1. Country Segmental Analysis
- 17.10.2. Vaccine Type
- 17.10.3. Technology Platform
- 17.10.4. Disease Indication
- 17.10.5. Delivery Method
- 17.10.6. Route of Administration
- 17.10.7. Dosage Form
- 17.10.8. Development Stage
- 17.10.9. End-users
- 17.11. Thailand mRNA Vaccines Market
- 17.11.1. Country Segmental Analysis
- 17.11.2. Vaccine Type
- 17.11.3. Technology Platform
- 17.11.4. Disease Indication
- 17.11.5. Delivery Method
- 17.11.6. Route of Administration
- 17.11.7. Dosage Form
- 17.11.8. Development Stage
- 17.11.9. End-users
- 17.12. Vietnam mRNA Vaccines Market
- 17.12.1. Country Segmental Analysis
- 17.12.2. Vaccine Type
- 17.12.3. Technology Platform
- 17.12.4. Disease Indication
- 17.12.5. Delivery Method
- 17.12.6. Route of Administration
- 17.12.7. Dosage Form
- 17.12.8. Development Stage
- 17.12.9. End-users
- 17.13. Rest of Asia Pacific mRNA Vaccines Market
- 17.13.1. Country Segmental Analysis
- 17.13.2. Vaccine Type
- 17.13.3. Technology Platform
- 17.13.4. Disease Indication
- 17.13.5. Delivery Method
- 17.13.6. Route of Administration
- 17.13.7. Dosage Form
- 17.13.8. Development Stage
- 17.13.9. End-users
- 18. Middle East mRNA Vaccines Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Middle East mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Vaccine Type
- 18.3.2. Technology Platform
- 18.3.3. Disease Indication
- 18.3.4. Delivery Method
- 18.3.5. Route of Administration
- 18.3.6. Dosage Form
- 18.3.7. Development Stage
- 18.3.8. End-users
- 18.3.9. Country
- 18.3.9.1. Turkey
- 18.3.9.2. UAE
- 18.3.9.3. Saudi Arabia
- 18.3.9.4. Israel
- 18.3.9.5. Rest of Middle East
- 18.4. Turkey mRNA Vaccines Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Vaccine Type
- 18.4.3. Technology Platform
- 18.4.4. Disease Indication
- 18.4.5. Delivery Method
- 18.4.6. Route of Administration
- 18.4.7. Dosage Form
- 18.4.8. Development Stage
- 18.4.9. End-users
- 18.5. UAE mRNA Vaccines Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Vaccine Type
- 18.5.3. Technology Platform
- 18.5.4. Disease Indication
- 18.5.5. Delivery Method
- 18.5.6. Route of Administration
- 18.5.7. Dosage Form
- 18.5.8. Development Stage
- 18.5.9. End-users
- 18.6. Saudi Arabia mRNA Vaccines Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Vaccine Type
- 18.6.3. Technology Platform
- 18.6.4. Disease Indication
- 18.6.5. Delivery Method
- 18.6.6. Route of Administration
- 18.6.7. Dosage Form
- 18.6.8. Development Stage
- 18.6.9. End-users
- 18.7. Israel mRNA Vaccines Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Vaccine Type
- 18.7.3. Technology Platform
- 18.7.4. Disease Indication
- 18.7.5. Delivery Method
- 18.7.6. Route of Administration
- 18.7.7. Dosage Form
- 18.7.8. Development Stage
- 18.7.9. End-users
- 18.8. Rest of Middle East mRNA Vaccines Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Vaccine Type
- 18.8.3. Technology Platform
- 18.8.4. Disease Indication
- 18.8.5. Delivery Method
- 18.8.6. Route of Administration
- 18.8.7. Dosage Form
- 18.8.8. Development Stage
- 18.8.9. End-users
- 19. Africa mRNA Vaccines Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Africa mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Vaccine Type
- 19.3.2. Technology Platform
- 19.3.3. Disease Indication
- 19.3.4. Delivery Method
- 19.3.5. Route of Administration
- 19.3.6. Dosage Form
- 19.3.7. Development Stage
- 19.3.8. End-users
- 19.3.9. Country
- 19.3.9.1. South Africa
- 19.3.9.2. Egypt
- 19.3.9.3. Nigeria
- 19.3.9.4. Algeria
- 19.3.9.5. Rest of Africa
- 19.4. South Africa mRNA Vaccines Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Vaccine Type
- 19.4.3. Technology Platform
- 19.4.4. Disease Indication
- 19.4.5. Delivery Method
- 19.4.6. Route of Administration
- 19.4.7. Dosage Form
- 19.4.8. Development Stage
- 19.4.9. End-users
- 19.5. Egypt mRNA Vaccines Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Vaccine Type
- 19.5.3. Technology Platform
- 19.5.4. Disease Indication
- 19.5.5. Delivery Method
- 19.5.6. Route of Administration
- 19.5.7. Dosage Form
- 19.5.8. Development Stage
- 19.5.9. End-users
- 19.6. Nigeria mRNA Vaccines Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Vaccine Type
- 19.6.3. Technology Platform
- 19.6.4. Disease Indication
- 19.6.5. Delivery Method
- 19.6.6. Route of Administration
- 19.6.7. Dosage Form
- 19.6.8. Development Stage
- 19.6.9. End-users
- 19.7. Algeria mRNA Vaccines Market
- 19.7.1. Country Segmental Analysis
- 19.7.2. Vaccine Type
- 19.7.3. Technology Platform
- 19.7.4. Disease Indication
- 19.7.5. Delivery Method
- 19.7.6. Route of Administration
- 19.7.7. Dosage Form
- 19.7.8. Development Stage
- 19.7.9. End-users
- 19.8. Rest of Africa mRNA Vaccines Market
- 19.8.1. Country Segmental Analysis
- 19.8.2. Vaccine Type
- 19.8.3. Technology Platform
- 19.8.4. Disease Indication
- 19.8.5. Delivery Method
- 19.8.6. Route of Administration
- 19.8.7. Dosage Form
- 19.8.8. Development Stage
- 19.8.9. End-users
- 20. South America mRNA Vaccines Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. Central and South Africa mRNA Vaccines Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
- 20.3.1. Vaccine Type
- 20.3.2. Technology Platform
- 20.3.3. Disease Indication
- 20.3.4. Delivery Method
- 20.3.5. Route of Administration
- 20.3.6. Dosage Form
- 20.3.7. Development Stage
- 20.3.8. End-users
- 20.3.9. Country
- 20.3.9.1. Brazil
- 20.3.9.2. Argentina
- 20.3.9.3. Rest of South America
- 20.4. Brazil mRNA Vaccines Market
- 20.4.1. Country Segmental Analysis
- 20.4.2. Vaccine Type
- 20.4.3. Technology Platform
- 20.4.4. Disease Indication
- 20.4.5. Delivery Method
- 20.4.6. Route of Administration
- 20.4.7. Dosage Form
- 20.4.8. Development Stage
- 20.4.9. End-users
- 20.5. Argentina mRNA Vaccines Market
- 20.5.1. Country Segmental Analysis
- 20.5.2. Vaccine Type
- 20.5.3. Technology Platform
- 20.5.4. Disease Indication
- 20.5.5. Delivery Method
- 20.5.6. Route of Administration
- 20.5.7. Dosage Form
- 20.5.8. Development Stage
- 20.5.9. End-users
- 20.6. Rest of South America mRNA Vaccines Market
- 20.6.1. Country Segmental Analysis
- 20.6.2. Vaccine Type
- 20.6.3. Technology Platform
- 20.6.4. Disease Indication
- 20.6.5. Delivery Method
- 20.6.6. Route of Administration
- 20.6.7. Dosage Form
- 20.6.8. Development Stage
- 20.6.9. End-users
- 21. Key Players/ Company Profile
- 21.1. Acuitas Therapeutics
- 21.1.1. Company Details/ Overview
- 21.1.2. Company Financials
- 21.1.3. Key Customers and Competitors
- 21.1.4. Business/ Industry Portfolio
- 21.1.5. Product Portfolio/ Specification Details
- 21.1.6. Pricing Data
- 21.1.7. Strategic Overview
- 21.1.8. Recent Developments
- 21.2. Arcturus Therapeutics Holdings Inc.
- 21.3. Argos Therapeutics Inc.
- 21.4. AstraZeneca plc
- 21.5. BioNTech SE
- 21.6. CureVac N.V.
- 21.7. eTheRNA Immunotherapies
- 21.8. Ethris GmbH
- 21.9. Gritstone bio Inc.
- 21.10. GSK plc (GlaxoSmithKline)
- 21.11. Merck & Co. Inc.
- 21.12. Moderna Inc.
- 21.13. Novartis AG
- 21.14. Pfizer Inc.
- 21.15. Providence Therapeutics Holdings Inc.
- 21.16. Sanofi S.A.
- 21.17. Stemirna Therapeutics
- 21.18. Translate Bio (Sanofi)
- 21.19. Walvax Biotechnology Co. Ltd.
- 21.20. Other Key Players
- 21.1. Acuitas Therapeutics
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase and Others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players product portfolio
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources includes primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
